Summary of findings 1: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes hand‐foot syndrome (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes neurological (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).
It is very uncertain whether summary of findings 2: PLD alone changes progression‐free survival (PFS) compared with other conventional chemotherapy (very low certainty).
Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
Chemotherapy with bevacizumab followed by bevacizumab maintenance leads to higher any adverse event (grade ≥3) compared with chemotherapy alone (high certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).
Chemotherapy with TKI followed by TKI maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).
Chemotherapy with bevacizumab probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
The review found no eligible studies for this question.